Since the<unk>  gene is located on the X chromosome, symptoms are seen almost exclusively in men. While there are a few exceptions, female carriers have a noticeable lack of pigmentation in the RPE but do not experience any symptoms. Female carriers have a 50% chance of having either an affected son or a carrier daughter, while a male with<unk>  will have all carrier daughters and unaffected sons. Even though the disease progression can vary significantly, there are general trends. The first symptom many individuals with<unk>  notice is a significant loss of night vision, which begins in youth. Peripheral vision loss occurs gradually, starting as a ring of vision loss, and continuing on to "tunnel vision" in adulthood. Individuals with<unk>  tend to maintain good visual acuity into their 40s, but eventually lose all sight at some point in the 50–70 age range. A study of 115 individuals with<unk>  found that 84% of patients under the age of 60 had a visual acuity of 20/40 or better, while 33% of patients over 60 years old had a visual acuity of 20/200 or worse. The most severe visual acuity impairment (only being able to count fingers or worse) did not occur until the seventh decade of life. The same study found the mean rate of visual acuity loss to be about 0.09 logMAR per 5 years, which is roughly 1 row on a Snellen chart.
Choroideremia
Fungemia
Granulocytosis
Thrombocythemia
Bandemia
Agranulocytosis
Lycopenemia
Asemia